Cargando…

Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study)

INTRODUCTION: Scabies is a significant contributor to global morbidity, affecting approximately 200 million people at any time. Scabies is endemic in many resource-limited tropical settings. Bacterial skin infection (impetigo) frequently complicates scabies infestation in these settings. Community-w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lake, Susanna J, Phelan, Sophie L, Engelman, Daniel, Sokana, Oliver, Nasi, Titus, Boara, Dickson, Gorae, Christina, Schuster, Tibor, Grobler, Anneke C, Osti, Millicent H, Andrews, Ross, Marks, Michael, Whitfeld, Margot J, Romani, Lucia, Kaldor, John, Steer, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462236/
https://www.ncbi.nlm.nih.gov/pubmed/32868360
http://dx.doi.org/10.1136/bmjopen-2020-037305
_version_ 1783576877283147776
author Lake, Susanna J
Phelan, Sophie L
Engelman, Daniel
Sokana, Oliver
Nasi, Titus
Boara, Dickson
Gorae, Christina
Schuster, Tibor
Grobler, Anneke C
Osti, Millicent H
Andrews, Ross
Marks, Michael
Whitfeld, Margot J
Romani, Lucia
Kaldor, John
Steer, Andrew
author_facet Lake, Susanna J
Phelan, Sophie L
Engelman, Daniel
Sokana, Oliver
Nasi, Titus
Boara, Dickson
Gorae, Christina
Schuster, Tibor
Grobler, Anneke C
Osti, Millicent H
Andrews, Ross
Marks, Michael
Whitfeld, Margot J
Romani, Lucia
Kaldor, John
Steer, Andrew
author_sort Lake, Susanna J
collection PubMed
description INTRODUCTION: Scabies is a significant contributor to global morbidity, affecting approximately 200 million people at any time. Scabies is endemic in many resource-limited tropical settings. Bacterial skin infection (impetigo) frequently complicates scabies infestation in these settings. Community-wide ivermectin-based mass drug administration (MDA) is an effective control strategy for scabies in island settings, with a single round of MDA reducing population prevalence by around 90%. However, current two-dose regimens present a number of barriers to programmatic MDA implementation. We designed the Regimens of Ivermectin for Scabies Elimination (RISE) trial to investigate whether one-dose MDA may be as effective as two-dose MDA in controlling scabies in high-prevalence settings. METHODS AND ANALYSIS: RISE is a cluster-randomised non-inferiority trial. The study will be conducted in 20 isolated villages in Western Province of Solomon Islands where population prevalence of scabies is approximately 20%. Villages will be randomly allocated to receive either one dose or two doses of ivermectin-based MDA in a 1:1 ratio. The primary objective of the study is to determine if ivermectin-based MDA with one dose is as effective as MDA with two doses in reducing the prevalence of scabies after 12 months. Secondary objectives include the effect of ivermectin-based MDA on impetigo prevalence after 12 and 24 months, the prevalence of scabies at 24 months after the intervention, the impact on presentation to health facilities with scabies and impetigo, and the safety of one-dose and two-dose MDA. ETHICS AND DISSEMINATION: This trial has been approved by the ethics review committees of the Solomon Islands and the Royal Children's Hospital, Australia. Results will be disseminated in peer-reviewed publications and in meetings with the Solomon Islands Ministry of Health and Medical Services and participating communities. TRIAL REGISTRATION DETAILS: Australian New Zealand Clinical Trials Registry: ACTRN12618001086257. Date registered: 28 June 2018.
format Online
Article
Text
id pubmed-7462236
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74622362020-09-11 Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study) Lake, Susanna J Phelan, Sophie L Engelman, Daniel Sokana, Oliver Nasi, Titus Boara, Dickson Gorae, Christina Schuster, Tibor Grobler, Anneke C Osti, Millicent H Andrews, Ross Marks, Michael Whitfeld, Margot J Romani, Lucia Kaldor, John Steer, Andrew BMJ Open Global Health INTRODUCTION: Scabies is a significant contributor to global morbidity, affecting approximately 200 million people at any time. Scabies is endemic in many resource-limited tropical settings. Bacterial skin infection (impetigo) frequently complicates scabies infestation in these settings. Community-wide ivermectin-based mass drug administration (MDA) is an effective control strategy for scabies in island settings, with a single round of MDA reducing population prevalence by around 90%. However, current two-dose regimens present a number of barriers to programmatic MDA implementation. We designed the Regimens of Ivermectin for Scabies Elimination (RISE) trial to investigate whether one-dose MDA may be as effective as two-dose MDA in controlling scabies in high-prevalence settings. METHODS AND ANALYSIS: RISE is a cluster-randomised non-inferiority trial. The study will be conducted in 20 isolated villages in Western Province of Solomon Islands where population prevalence of scabies is approximately 20%. Villages will be randomly allocated to receive either one dose or two doses of ivermectin-based MDA in a 1:1 ratio. The primary objective of the study is to determine if ivermectin-based MDA with one dose is as effective as MDA with two doses in reducing the prevalence of scabies after 12 months. Secondary objectives include the effect of ivermectin-based MDA on impetigo prevalence after 12 and 24 months, the prevalence of scabies at 24 months after the intervention, the impact on presentation to health facilities with scabies and impetigo, and the safety of one-dose and two-dose MDA. ETHICS AND DISSEMINATION: This trial has been approved by the ethics review committees of the Solomon Islands and the Royal Children's Hospital, Australia. Results will be disseminated in peer-reviewed publications and in meetings with the Solomon Islands Ministry of Health and Medical Services and participating communities. TRIAL REGISTRATION DETAILS: Australian New Zealand Clinical Trials Registry: ACTRN12618001086257. Date registered: 28 June 2018. BMJ Publishing Group 2020-08-30 /pmc/articles/PMC7462236/ /pubmed/32868360 http://dx.doi.org/10.1136/bmjopen-2020-037305 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Global Health
Lake, Susanna J
Phelan, Sophie L
Engelman, Daniel
Sokana, Oliver
Nasi, Titus
Boara, Dickson
Gorae, Christina
Schuster, Tibor
Grobler, Anneke C
Osti, Millicent H
Andrews, Ross
Marks, Michael
Whitfeld, Margot J
Romani, Lucia
Kaldor, John
Steer, Andrew
Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study)
title Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study)
title_full Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study)
title_fullStr Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study)
title_full_unstemmed Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study)
title_short Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study)
title_sort protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the rise study)
topic Global Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462236/
https://www.ncbi.nlm.nih.gov/pubmed/32868360
http://dx.doi.org/10.1136/bmjopen-2020-037305
work_keys_str_mv AT lakesusannaj protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT phelansophiel protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT engelmandaniel protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT sokanaoliver protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT nasititus protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT boaradickson protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT goraechristina protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT schustertibor protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT groblerannekec protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT ostimillicenth protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT andrewsross protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT marksmichael protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT whitfeldmargotj protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT romanilucia protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT kaldorjohn protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy
AT steerandrew protocolforaclusterrandomisednoninferioritytrialofoneversustwodosesofivermectinforthecontrolofscabiesusingamassdrugadministrationstrategytherisestudy